News

Sancuso (SP-01) is a long-acting transdermal system, delivering the anti-emetic, granisetron, steadily into the patient’s bloodstream over seven days without the need for injections or swallowing pills. Sancuso

Greenway Medical Technologies has announced that it will be deploying its electronic health record solution, PrimeSuite, into Pediatric Associates of Washington State. With this implementation, Pediatric Associates’s eight

Trelstar 22.5mg is a six-month slow release, injectable, luteinizing hormone-releasing hormone agonist indicated for the palliative treatment of advanced prostate cancer. Paladin obtained the Canadian license for Trelstar

The company’s wrinkles or nasolabial folds Phase III trials were conducted under an FDA special protocol assessment. Isolagen currently estimates that its unrestricted, available cash resources will allow

DiaMedica said that Dr Waters is an experienced scientist and pharmaceutical industry executive with more than 24 years of active leadership and involvement in drug development. Dr Waters’s

The company reported a net loss of $38.1 million, or $0.49 per share, for the full year 2008, compared to a net loss of $33.9 million, or $0.47

Net loss for the year 2008 was $8.42 million, or $0.71 per share, compared to a net loss of $8.94 million, or $0.80 per share, for 2007. The

Isolagen, an aesthetic and therapeutic company, has announced positive top-line efficacy results from a Phase II/III clinical study of the Isolagen Therapy for the treatment of moderate to

MiddleBrook Pharmaceuticals, a developer and marketer of anti-infective products, has reported net loss of $11.6m for the fourth quarter of 2008, compared to a net loss of $9.1m